Jingxin Pharmaceutical: Announcement on the inclusion of didacinib capsules in the national medical insurance catalogue
Jingxin Pharmaceutical: Report for the third quarter of 2024
Jingxin Pharmaceutical: Announcement on cancellation of majority shareholders\' share pledges
Jingxin Pharmaceutical: Ping An Securities Co., Ltd.\'s inspection opinion on the listing and circulation of Jingxin Pharmaceutical\'s non-public restricted shares
Jingxin Pharmaceutical: An indicative announcement on the listing and circulation of restricted non-public shares in 2020
Zhejiang Jingxin Pharmaceutical: Investor relations management information of Zhejiang Jingxin Pharmaceutical as of August 16, 2024.
Zhejiang Jingxin Pharmaceutical: Summary table of non-operating funds utilization and other related funds flow for the first half of the year.
Zhejiang Jingxin Pharmaceutical: Announcement regarding increase in entrusted wealth management limit of idle proprietary funds.
Zhejiang Jingxin Pharmaceutical: Special report on the collection and use of funds for the first half of 2024.
Zhejiang Jingxin Pharmaceutical: Announcement of the resolution of the Supervisory Board on the semi-annual report.
Zhejiang Jingxin Pharmaceutical: Announcement of Board of Directors' resolution for semi-annual report.
Zhejiang Jingxin Pharmaceutical: Half-year report for the year 2024.
Zhejiang Jingxin Pharmaceutical: Financial Report for the first half of 2024.
Zhejiang Jingxin Pharmaceutical: Ping An Securities Co., Ltd.'s verification opinion on Zhejiang Jingxin Pharmaceutical Co., Ltd.'s use of some idle funds raised to temporarily supplement working capital.
Zhejiang Jingxin Pharmaceutical: Summary of Half-Year Report in 2024.
Zhejiang Jingxin Pharmaceutical: Announcement on the Temporary Supplement of Working Capital with Some Unused Raised Funds
Zhejiang Jingxin Pharmaceutical: Announcement regarding the return of raised funds.
Zhejiang Jingxin Pharmaceutical: Announcement regarding the release of pledged shares by major shareholders.
Zhejiang Jingxin Pharmaceutical: Announcement Regarding Enrofloxacin Active Pharmaceutical Ingredient, a wholly-owned subsidiary, obtaining the European CEP certificate.
Zhejiang Jingxin Pharmaceutical: 2023 Annual Equity Distribution Implementation Notice
No Data